Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update
Revenue rises 24% quarter over quarter as Third quarter operating loss improves 18% year over year on cost reductions; Company regained compliance with Nasdaq stockholders’ equity requirementManagement to Host Conference Call today at 5:00 pm ETLITTLETON, Colo., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Vi…